Cargando…
Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
[Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they req...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482319/ https://www.ncbi.nlm.nih.gov/pubmed/34608447 http://dx.doi.org/10.1021/acsomega.1c01253 |
_version_ | 1784576876787793920 |
---|---|
author | Cate, David M. Bishop, Joshua D. Hsieh, Helen V. Glukhova, Veronika A. Alonzo, Luis F. Hermansky, H. Gleda Barrios-Lopez, Brianda Grant, Benjamin D. Anderson, Caitlin E. Spencer, Ethan Kuhn, Samantha Gallagher, Ryan Rivera, Rafael Bennett, Crissa Byrnes, Samantha A. Connelly, John T. Dewan, Puneet K. Boyle, David S. Weigl, Bernhard H. Nichols, Kevin P. |
author_facet | Cate, David M. Bishop, Joshua D. Hsieh, Helen V. Glukhova, Veronika A. Alonzo, Luis F. Hermansky, H. Gleda Barrios-Lopez, Brianda Grant, Benjamin D. Anderson, Caitlin E. Spencer, Ethan Kuhn, Samantha Gallagher, Ryan Rivera, Rafael Bennett, Crissa Byrnes, Samantha A. Connelly, John T. Dewan, Puneet K. Boyle, David S. Weigl, Bernhard H. Nichols, Kevin P. |
author_sort | Cate, David M. |
collection | PubMed |
description | [Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow (immuno)assays (LFAs) in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8482319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-84823192021-09-30 Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein Cate, David M. Bishop, Joshua D. Hsieh, Helen V. Glukhova, Veronika A. Alonzo, Luis F. Hermansky, H. Gleda Barrios-Lopez, Brianda Grant, Benjamin D. Anderson, Caitlin E. Spencer, Ethan Kuhn, Samantha Gallagher, Ryan Rivera, Rafael Bennett, Crissa Byrnes, Samantha A. Connelly, John T. Dewan, Puneet K. Boyle, David S. Weigl, Bernhard H. Nichols, Kevin P. ACS Omega [Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow (immuno)assays (LFAs) in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2. American Chemical Society 2021-09-21 /pmc/articles/PMC8482319/ /pubmed/34608447 http://dx.doi.org/10.1021/acsomega.1c01253 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Cate, David M. Bishop, Joshua D. Hsieh, Helen V. Glukhova, Veronika A. Alonzo, Luis F. Hermansky, H. Gleda Barrios-Lopez, Brianda Grant, Benjamin D. Anderson, Caitlin E. Spencer, Ethan Kuhn, Samantha Gallagher, Ryan Rivera, Rafael Bennett, Crissa Byrnes, Samantha A. Connelly, John T. Dewan, Puneet K. Boyle, David S. Weigl, Bernhard H. Nichols, Kevin P. Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein |
title | Antibody Screening Results for Anti-Nucleocapsid Antibodies
Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2
Nucleocapsid Protein |
title_full | Antibody Screening Results for Anti-Nucleocapsid Antibodies
Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2
Nucleocapsid Protein |
title_fullStr | Antibody Screening Results for Anti-Nucleocapsid Antibodies
Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2
Nucleocapsid Protein |
title_full_unstemmed | Antibody Screening Results for Anti-Nucleocapsid Antibodies
Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2
Nucleocapsid Protein |
title_short | Antibody Screening Results for Anti-Nucleocapsid Antibodies
Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2
Nucleocapsid Protein |
title_sort | antibody screening results for anti-nucleocapsid antibodies
toward the development of a lateral flow assay to detect sars-cov-2
nucleocapsid protein |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482319/ https://www.ncbi.nlm.nih.gov/pubmed/34608447 http://dx.doi.org/10.1021/acsomega.1c01253 |
work_keys_str_mv | AT catedavidm antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT bishopjoshuad antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT hsiehhelenv antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT glukhovaveronikaa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT alonzoluisf antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT hermanskyhgleda antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT barrioslopezbrianda antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT grantbenjamind antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT andersoncaitline antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT spencerethan antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT kuhnsamantha antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT gallagherryan antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT riverarafael antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT bennettcrissa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT byrnessamanthaa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT connellyjohnt antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT dewanpuneetk antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT boyledavids antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT weiglbernhardh antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein AT nicholskevinp antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein |